Clinical Trials in Nashville

Showing 4861-4880 of 15,379 trials

Metabolic Effects of Natriuretic Peptide Hormones

NCT03397966

Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on metabolism in humans. Therefore, the investigators propose a study to determine the effects of b-type natriuretic peptide (BNP) on energy and fat metabolism in humans. The investigators' primary hypothesis is that the administration of BNP will increase energy expenditure in humans. The investigators' secondary hypothesis is that BNP administration will promote changes in gene expression in fat tissue suggestive of fat "beiging" in humans. Interventions that safely increase energy expenditure and promote fat "beiging" represent potential strategies for treating metabolic dysfunction due to obesity.

ObesityCardiovascular Physiological PhenomenaMetabolism

VA Office of Research and Development5 participantsStarted Jul 2018

Nashville, Tennessee, United States • Nashville, Tennessee, United States

TERMINATEDPhase 1< 1 mile

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

NCT02702492

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

Solid TumorsNHL

Karyopharm Therapeutics Inc60 participantsStarted Jun 2016

Los Angeles, California, United States • Aurora, Colorado, United States • Washington D.C., District of Columbia, United States +5 more locations

Metabolic Effects of Natriuretic Peptide Hormones

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Find Trials by Condition in Nashville

First in Human Study of M1069 in Advanced Solid Tumors

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

FPA150 in Patients With Advanced Solid Tumors

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

Observational Study to Assess Migraine Prediction Tool

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)